Company intelligence / Profile preview
BioAge Labs
Richmond, California, United States
- Ownership
- Public · BIOA
- Development stage
- Phase 2
01
Overview
BioAge discontinued the STRIDES Phase 2 clinical trial for azelaprag in December 2024 due to liver transaminitis observations. The company is now advancing BGE-102, an oral brain-penetrant NLRP3 inhibitor, with Phase 1 SAD data expected by end of 2025. They are also developing next-generation APJ agonists.
- Therapeutic areas
- OtherEndocrinologyCardiovascularMetabolic Disorders
- Modalities
- small moleculesantibody therapeutics
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
NovartisLilly ExploR&D (part of Lilly Catalyze360)
04
Financials
- Market cap
- $353.7M
- Total revenue
- $2.5M
- Enterprise value
- $37.8M
Beyond the preview
Go deeper on BioAge Labs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioAge Labs.